Moderna Announces Encouraging Phase 1/2 Results for Combo Influenza and COVID-19 Vaccine
Moderna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommendation is grounded in pre-clinical
Read moreMcMaster University and the Massachusetts Institute of Technology researchers using artificial intelligence (AI) have discovered a new type of antibiotic
Read moreJapanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read morePfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
Read moreThe acquisition agreement is set to expand Aegis’s toxicology portfolio, while HealthTrackRx expands its PCR infectious disease testing. Aegis Sciences
Read moreThermo Fisher Scientific, the global leader in serving science, announced the launch of the TrueMark Infectious Disease Research Panels designed
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read moreThe US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Novavax’s adjuvanted Covid-19 vaccine, NVX-CoV2373, as
Read more